Tempest Therapeutics
TPST
31 hedge funds and large institutions have $9.88M invested in Tempest Therapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 9 closing their positions.
842% more capital invested
Capital invested by funds: $1.05M → $9.88M (+$8.83M)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
35% more funds holding
Funds holding: 23 → 31 (+8)
1.07% less ownership
Funds ownership: 1.97% → 0.9% (-1.1%)
19% less call options, than puts
Call options by funds: $376K | Put options by funds: $466K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.55M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$511K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$385K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$380K |
| 5 |
Two Sigma Investments
New York
|
+$315K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$786K |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$284K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$163K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$163K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$132K |
TPST Hedge Fund Activity: Q4 2023 in Review
31 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2023, worth a combined $9.88M — up 842% from $1.05M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TPST positions and 9 closed out — a net gain of 8 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $1.55M. The largest seller was Fidelity Investments, cutting an estimated $786K.
- 31 institutional investors held Tempest Therapeutics (TPST) as of Q4 2023, up from 23 in Q3 2023.
- Funds reported $9.88M of Tempest Therapeutics stock for Q4 2023, up 842% quarter-over-quarter.
- 17 funds opened new Tempest Therapeutics positions in Q4 2023 and 9 closed out, a net change of +8 holders.
- The largest Tempest Therapeutics buyer in Q4 2023 was BlackRock, an estimated $1.55M added.
- The largest Tempest Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $786K sold.
Based on aggregated 13F filings for Q4 2023.